Human SMN1 Protein, His Tag
Cat. No. SM1-H5145
| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| SMN1 | Human SMN1 Protein, His Tag | Human | E. coli | ![]() | SDS-PAGE | $310.00 100ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| vesemnogene lantuparvovec | AAV-hSMN1 | Phase 3 Clinical | Lantu Biopharma Inc | Muscular Atrophy, Spinal | 詳細 |
| Salanersen | BIIB-115; ION-306 | Phase 3 Clinical | Ionis Pharmaceuticals Inc | Muscular Atrophy, Spinal | 詳細 |
| Branaplam | LMI-070; NVP-LMI070-AAA; NVP-LMI070-NX; NVS-SM1 | Phase 2 Clinical | Novartis Pharma Ag | Huntington Disease; Muscular Atrophy, Spinal | 詳細 |
| GB-221 (GEMMA Biotherapeutics) | GB-221 | Phase 2 Clinical | Gemma Biotherapeutics Inc | Spinal Muscular Atrophies of Childhood | 詳細 |
| ANB-004 | ANB-004 | Phase 2 Clinical | BIOCAD JSC | Muscular Atrophy, Spinal | 詳細 |
| EXG001-307 | EXG001-307 | Phase 2 Clinical | Exegenesis Bio Inc | Muscular Atrophy, Spinal | 詳細 |
| SMN-C3 | SMN-C3 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, Ptc Therapeutics Inc | Muscular Atrophy, Spinal | 詳細 |
| SKG-0201 | SKG-0201; SKG0201 | Phase 1 Clinical | Skyline Therapeutics (Hong Kong) Ltd | Muscular Atrophy, Spinal; Spinal Muscular Atrophies of Childhood | 詳細 |
| GCB-001 | GCB-001; GCB001 | Clinical | Shanghai Jinke Bo Biotechnology Co Ltd | Spinal Muscular Atrophies of Childhood | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Risdiplam | RG-7916; RO-7034067 | Approved | Ptc Therapeutics Inc | EVRYSDI, 艾满欣 | United States | Muscular Atrophy, Spinal | Genentech Inc | 2020-08-07 | Muscular Atrophy, Spinal | 詳細 |
| Nusinersen sodium | BIIB-058; ISIS-396443 | Approved | Ionis Pharmaceuticals Inc | Spinraza | United States | Muscular Atrophy, Spinal | Biogen Idec | 2016-12-23 | Muscular Atrophy, Spinal | 詳細 |
| Onasemnogene abeparvovec | AVXS-101; scAAV-9.CB.SMN; OAV101; rAAV-9 | Approved | Novartis Gene Therapies Inc, Novartis Pharma Ag | Zolgensma, Itvisma | United States | Muscular Atrophy, Spinal | Novartis Gene Therapies Inc | 2019-05-24 | Muscular Atrophy, Spinal; Spinal Muscular Atrophies of Childhood | 詳細 |